Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for
patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the …

Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …

Our understanding of tumor-infiltrating lymphocytes (TILs) is rapidly expanding beyond T cell-
centric perspectives to include B cells and plasma cells, collectively referred to as TIL-Bs. In …

Long noncoding RNAs (lncRNAs) have been associated with cancer immunity regulation
and the tumor microenvironment (TME). However, functions of lncRNAs of tumor-infiltrating …

Purpose: The addition of immune checkpoint blockade (ICB) to platinum/etoposide
chemotherapy changed the standard of care for small cell lung cancer (SCLC) treatment …

Lung cancer is the most malignant human cancer worldwide, also with the highest incidence
rate. However, small-cell lung cancer (SCLC) accounts for 14% of all lung cancer cases …

Small-cell lung cancer (SCLC) is characterized by aggressive disease progression and
tendency to metastasize. Although chemotherapy for extensive-stage SCLC (ES-SCLC) has …

Small cell lung cancer (SCLC), an aggressive and devastating malignancy, is characterized
by rapid growth and early metastasis. Although most patients respond to first-line …